Screener
Nektar Therapeutics NKTR Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $149,578 | $15,116 |
| Short-term investments | 419,026 | 230,636 |
| Other current assets (including $432 and $429 as of March 31, 2026 and December 31, 2025, respectively, from a related party) | 20,437 | 20,514 |
| Total current assets | 589,041 | 266,266 |
| Long-term investments | 162,993 | — |
| Other assets | 11,237 | 14,140 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's short-term investments?
- Nektar Therapeutics (NKTR) reported short-term investments of $419.03M in Q1 2026.
- How has Nektar Therapeutics's short-term investments changed year-over-year?
- Nektar Therapeutics's short-term investments increased by 133.1% year-over-year, from $179.74M to $419.03M.
- What is the long-term trend for Nektar Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Nektar Therapeutics's short-term investments has grown at a -23.2% compound annual growth rate (CAGR), from $862.94M to $230.64M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Nektar Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude